K Pharma (4896) · TargetRestated
Establishment of an in-house manufacturing and marketing model in Japan for the regenerative medicine business
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Domestic In-House Manufacturing and Sales Model for the Regenerative Medicine BusinessA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Particularly in the domestic regenerative medicine business, we will pursue initiatives to manufacture and market products in-house over the medium to long term.」
The company continues to target in-house manufacturing and marketing in the domestic regenerative medicine business over the medium to long term. - FY2024RestatedAnnual report
「Particularly in the domestic regenerative medicine business, we will pursue initiatives to manufacture and market products in-house over the medium to long term.」
The company continues its policy of pursuing in-house manufacturing and marketing in the domestic regenerative medicine business in addition to a licensing model. - FY2023First statedAnnual report
「Particularly in the domestic regenerative medicine business, we will pursue initiatives to manufacture and market products in-house over the medium to long term.」
For the domestic regenerative medicine business, the company intends to pursue in-house manufacturing and marketing in addition to a licensing model.